Reported Earnings • Apr 25
First quarter 2026 earnings released: CN¥0.19 loss per share (vs CN¥0.12 profit in 1Q 2025) First quarter 2026 results: CN¥0.19 loss per share (down from CN¥0.12 profit in 1Q 2025). Revenue: CN¥836.2m (down 48% from 1Q 2025). Net loss: CN¥141.8m (down 257% from profit in 1Q 2025). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Announcement • Mar 30
KPC Pharmaceuticals,Inc. to Report Q1, 2026 Results on Apr 25, 2026 KPC Pharmaceuticals,Inc. announced that they will report Q1, 2026 results on Apr 25, 2026 New Risk • Mar 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 75% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.3% net profit margin). Major Estimate Revision • Mar 26
Consensus revenue estimates fall by 21% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥8.66b to CN¥6.82b. EPS estimate fell from CN¥0.843 to CN¥0.485 per share. Net income forecast to grow 4.8% next year vs 23% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥21.36 to CN¥16.15. Share price fell 5.7% to CN¥11.24 over the past week. Price Target Changed • Mar 23
Price target decreased by 26% to CN¥16.15 Down from CN¥21.83, the current price target is provided by 1 analyst. New target price is 44% above last closing price of CN¥11.22. Stock is down 35% over the past year. The company is forecast to post earnings per share of CN¥0.48 for next year compared to CN¥0.46 last year. Reported Earnings • Mar 20
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.46 (down from CN¥0.86 in FY 2024). Revenue: CN¥6.58b (down 22% from FY 2024). Net income: CN¥349.9m (down 46% from FY 2024). Profit margin: 5.3% (down from 7.7% in FY 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 45%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 07
Full year 2025 earnings released: EPS: CN¥0.46 (vs CN¥0.86 in FY 2024) Full year 2025 results: EPS: CN¥0.46 (down from CN¥0.86 in FY 2024). Revenue: CN¥6.58b (down 22% from FY 2024). Net income: CN¥349.9m (down 46% from FY 2024). Profit margin: 5.3% (down from 7.7% in FY 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Dec 26
KPC Pharmaceuticals,Inc. to Report Fiscal Year 2025 Results on Mar 20, 2026 KPC Pharmaceuticals,Inc. announced that they will report fiscal year 2025 results on Mar 20, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: CN¥0.099 (vs CN¥0.21 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.099 (down from CN¥0.21 in 3Q 2024). Revenue: CN¥1.40b (down 26% from 3Q 2024). Net income: CN¥71.0m (down 55% from 3Q 2024). Profit margin: 5.1% (down from 8.3% in 3Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Sep 30
KPC Pharmaceuticals,Inc. to Report Q3, 2025 Results on Oct 25, 2025 KPC Pharmaceuticals,Inc. announced that they will report Q3, 2025 results on Oct 25, 2025 Declared Dividend • Jul 28
Dividend increased to CN¥0.30 Dividend of CN¥0.30 is 50% higher than last year. Ex-date: 30th July 2025 Payment date: 30th July 2025 Dividend yield will be 2.0%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (37% earnings payout ratio) and cash flows (33% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 71% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 30
KPC Pharmaceuticals,Inc. to Report First Half, 2025 Results on Aug 23, 2025 KPC Pharmaceuticals,Inc. announced that they will report first half, 2025 results on Aug 23, 2025 Announcement • May 29
KPC Pharmaceuticals,Inc., Annual General Meeting, Jun 20, 2025 KPC Pharmaceuticals,Inc., Annual General Meeting, Jun 20, 2025, at 10:00 China Standard Time. Location: The Company's Management Center, Kunming, Yunnan China Reported Earnings • May 02
First quarter 2025 earnings released: EPS: CN¥0.12 (vs CN¥0.16 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.12 (down from CN¥0.16 in 1Q 2024). Revenue: CN¥1.61b (down 13% from 1Q 2024). Net income: CN¥90.5m (down 24% from 1Q 2024). Profit margin: 5.6% (down from 6.4% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year. Announcement • Mar 28
KPC Pharmaceuticals,Inc. to Report Q1, 2025 Results on Apr 29, 2025 KPC Pharmaceuticals,Inc. announced that they will report Q1, 2025 results on Apr 29, 2025 Price Target Changed • Mar 12
Price target increased by 9.8% to CN¥23.80 Up from CN¥21.68, the current price target is provided by 1 analyst. New target price is 36% above last closing price of CN¥17.56. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥0.73 for next year compared to CN¥0.59 last year. Announcement • Dec 27
KPC Pharmaceuticals,Inc. to Report Fiscal Year 2024 Results on Mar 12, 2025 KPC Pharmaceuticals,Inc. announced that they will report fiscal year 2024 results on Mar 12, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.21 (down from CN¥0.22 in 3Q 2023). Revenue: CN¥1.90b (up 3.4% from 3Q 2023). Net income: CN¥157.9m (down 2.9% from 3Q 2023). Profit margin: 8.3% (down from 8.8% in 3Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Announcement • Sep 30
KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024 KPC Pharmaceuticals,Inc. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥14.68, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 74% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.33 per share. New Risk • Sep 13
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 36% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Aug 23
Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.12 in 2Q 2023). Revenue: CN¥1.70b (down 8.5% from 2Q 2023). Net income: CN¥110.8m (up 20% from 2Q 2023). Profit margin: 6.5% (up from 5.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥14.72, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 61% over the past three years. Declared Dividend • Jul 25
Dividend increased to CN¥0.20 Dividend of CN¥0.20 is 25% higher than last year. Ex-date: 31st July 2024 Payment date: 31st July 2024 Dividend yield will be 1.2%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 104% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 28
KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024 KPC Pharmaceuticals,Inc. announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Jun 02
KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024 KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024, at 10:00 China Standard Time. Price Target Changed • Apr 24
Price target decreased by 7.1% to CN¥25.01 Down from CN¥26.91, the current price target is an average from 2 analysts. New target price is 16% above last closing price of CN¥21.60. Stock is up 12% over the past year. The company is forecast to post earnings per share of CN¥0.80 for next year compared to CN¥0.59 last year. Announcement • Mar 29
KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024 KPC Pharmaceuticals,Inc announced that they will report Q1, 2024 results on Apr 27, 2024 Reported Earnings • Mar 23
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.59 (up from CN¥0.51 in FY 2022). Revenue: CN¥7.70b (down 7.0% from FY 2022). Net income: CN¥444.7m (up 16% from FY 2022). Profit margin: 5.8% (up from 4.6% in FY 2022). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings. Announcement • Dec 30
KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024 KPC Pharmaceuticals,Inc announced that they will report fiscal year 2023 results on Mar 22, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: CN¥1.84b (down 9.2% from 3Q 2022). Net income: CN¥162.6m (up 95% from 3Q 2022). Profit margin: 8.8% (up from 4.1% in 3Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥21.24, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 146% over the past three years. New Risk • Sep 12
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.14 in 2Q 2022). Revenue: CN¥1.86b (flat on 2Q 2022). Net income: CN¥92.3m (down 9.6% from 2Q 2022). Profit margin: 5.0% (down from 5.5% in 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥15.91, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 48% over the past three years. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥17.80, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 71% over the past three years. Announcement • Jun 28
KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023 KPC Pharmaceuticals,Inc announced that they will report first half, 2023 results on Aug 30, 2023 Valuation Update With 7 Day Price Move • May 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥23.22, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 152% over the past three years. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥20.71, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 127% over the past three years. Reported Earnings • Mar 23
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.51 (down from CN¥0.67 in FY 2021). Revenue: CN¥8.28b (flat on FY 2021). Net income: CN¥383.2m (down 25% from FY 2021). Profit margin: 4.6% (down from 6.2% in FY 2021). Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 27%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥16.64, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 66% over the past three years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 5 independent directors (6 non-independent directors). Chairman Si Yang Wang was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.21 (up from CN¥0.13 in 3Q 2021). Revenue: CN¥1.97b (up 1.6% from 3Q 2021). Net income: CN¥156.1m (up 53% from 3Q 2021). Profit margin: 7.9% (up from 5.3% in 3Q 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year. Reported Earnings • Aug 18
Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.14 (down from CN¥0.18 in 2Q 2021). Revenue: CN¥1.86b (down 15% from 2Q 2021). Net income: CN¥102.1m (down 26% from 2Q 2021). Profit margin: 5.5% (down from 6.2% in 2Q 2021). Over the next year, revenue is forecast to grow 17%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥13.02, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 27% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 5 independent directors (6 non-independent directors). Chairman Si Yang Wang was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 17
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.15 (down from CN¥0.26 in 1Q 2021). Revenue: CN¥2.36b (up 25% from 1Q 2021). Net income: CN¥114.5m (down 41% from 1Q 2021). Profit margin: 4.8% (down from 10% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.0%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 9.2%, compared to a 27% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥11.88, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 101% over the past three years. Reported Earnings • Oct 25
Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥1.93b (down 3.3% from 3Q 2020). Net income: CN¥101.8m (down 20% from 3Q 2020). Profit margin: 5.3% (down from 6.3% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 15
Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥2.20b (up 18% from 2Q 2020). Net income: CN¥137.2m (up 3.3% from 2Q 2020). Profit margin: 6.2% (down from 7.2% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥10.22, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 27x in the Pharmaceuticals industry in China. Total returns to shareholders of 42% over the past three years. Reported Earnings • Apr 18
First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.90b (up 21% from 1Q 2020). Net income: CN¥194.9m (up 112% from 1Q 2020). Profit margin: 10% (up from 5.9% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Mar 17
New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million. New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million on March 14, 2021. Post completion, KPC Pharmaceuticals, Inc. will hold 2.4845% stake of Nanjing Weili Zhibo Biotechnology Co., Ltd. The Board of Directors of KPC Pharmaceuticals, Inc. has approved the transaction. Reported Earnings • Mar 17
Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019) The company reported a mediocre full year result with weaker revenues, although earnings were flat and profit margins improved. Full year 2020 results: Revenue: CN¥7.72b (down 5.0% from FY 2019). Net income: CN¥456.9m (flat on FY 2019). Profit margin: 5.9% (up from 5.6% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 01
New 90-day low: CN¥8.34 The company is down 11% from its price of CN¥9.34 on 03 November 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Announcement • Jan 21
KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021 KPC Pharmaceuticals, Inc. announced that they will report fiscal year 2020 results on Mar 16, 2021 Is New 90 Day High Low • Jan 13
New 90-day low: CN¥8.38 The company is down 15% from its price of CN¥9.84 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Dec 14
New 90-day low: CN¥9.12 The company is down 9.0% from its price of CN¥10.06 on 15 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. Is New 90 Day High Low • Oct 27
New 90-day low: CN¥9.54 The company is down 12% from its price of CN¥10.81 on 29 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. Reported Earnings • Oct 22
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥445.5m, up 3.8% from the prior year. Total revenue was CN¥7.78b over the last 12 months, largely unchanged from the prior year. Announcement • Oct 19
KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020 KPC Pharmaceuticals, Inc. announced that they will report Q3, 2020 results on Oct 22, 2020 Announcement • Oct 02
A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million. A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million on September 29, 2020. Kunming Yinnuo Pharmaceutical Technology generated the net loss of CNY 3.6 million, net assets of CNY 107 million and total assets of CNY 114.9 million for the year ended December 31, 2019. Kunming Yinnuo Pharmaceutical Technology has total assets of CNY 164.9 million and net assets of CNY 105.7 million as of May 31, 2020. The transaction has been approved by the Board of Directors of KPC Pharmaceuticals. Announcement • Sep 08
KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd. KPC Pharmaceuticals, Inc. (SHSE:600422) agreed to acquire 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd. on August 14, 2019. KPC Pharmaceuticals, Inc. 9th directorate’s 14th meeting was held on August 14, 2019 and unanimously approved the transaction..
KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd. on August 14, 2020. Announcement • Jul 08
KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020 KPC Pharmaceuticals, Inc. announced that they will report first half, 2020 results on Aug 21, 2020